NEW YORK (GenomeWeb) – Myriad and Tufts Health Plan have signed a three-year contract under which Prolaris will be covered for men diagnosed with localized prostate cancer.

Prolaris measures the expression levels of multiple genes involved with cancer cell proliferation and scores how aggressive a patient's prostate cancer is. The test is meant to be used alongside other clinical assessments, such as Gleason score and prostate-specific antigen testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.